Chainlink developed a system that automates dividend payments for tokenized equities across four different blockchains, showcased at the Swift Hackathon. This solution addresses corporate actions like dividends, stock splits, and mergers, reducing errors common in traditional multi-party processing. The multi-chain capability ensures accurate payments regardless of where token holders keep their assets. Chainlink's ongoing collaboration with Swift and other institutions aims to streamline corporate actions processing, a $58 billion annual industry challenge, potentially improving tokenized asset management significantly if adopted in live workflows.
Chainlink's tokenized equity compliance solution is presented alongside Pluang's market data for context. As of Oct 02, 2026 01:41 WIB, among 50 major cryptocurrencies tradable on Pluang, 29 rose and 20 fell. Notable movers include EOS with a 1-day change of +8.13% and a typical hold time of 87 days, AAVE up 6.65% with a 40% sell and 60% buy order activity, and DOT down 3.71% with a 69% buy order activity and a typical hold time of 121 days.
Wells Fargo initiated coverage on BlackRock with an 'Overweight' rating, highlighting it as a good entry point for investors. Analysts expect BlackRock's Q3 earnings per share to rise to $14.25 from $11.55 a year ago, with revenue projected at $7.56 ...
Nike reported earnings per share of $0.48, beating estimates, but revenue fell short at $11.21 billion due to weak demand in Greater China and rising competition. The company issued a cautious fiscal 2027 outlook with EPS forecast between $1.15 and $...
NETSOL Technologies reported a record $20.7 million revenue in fiscal 2026 Q4, with net income rising 45.9% to $3.8 million. The company improved its gross margin to 63.6% and operating margin to 21.6%, reflecting enhanced profitability. For fiscal 2...
On October 1, 2026, Nexalin Technology surged 76.4% after securing a 10-year exclusive deal for its medical device in South America. Armada Acquisition Corp. II jumped 42.9% following shareholder approval of its merger with Evernorth, expected to clo...
Jefferies analyst Roger Song set a $150 price target for Nektar Therapeutics, suggesting a 219% upside from its $46.99 trading price. This comes after Nektar presented positive six-month Phase IIb trial results for its alopecia drug REZPEG, which als...
